Explore
Validate
LearnMAB376-100
antibody from R&D Systems
Targeting: CCL27
ALP, CTACK, CTAK, ESkine, ILC, PESKY, SCYA27, skinkine
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB376-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human CCL27/CTACK Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human CCL27/CTACK in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human CCL1, 2, 3, 4, 5, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, recombinant mouse CCL1, 2, 3, 4, 5, 6, 7, 9/10, 11, 12, 17, 19, 20, 21, 22, 24, 25, or recombinant rat CCL20 is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
NP_006655- Isotype
- IgG
- Antibody clone number
- 124308
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references CCL27/CCL28-CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells.
Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity.
Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.
Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.
Karnezis T, Farnsworth RH, Harris NC, Williams SP, Caesar C, Byrne DJ, Herle P, Macheda ML, Shayan R, Zhang YF, Yazar S, Takouridis SJ, Gerard C, Fox SB, Achen MG, Stacker SA
Cancer research 2019 Apr 1;79(7):1558-1572
Cancer research 2019 Apr 1;79(7):1558-1572
Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity.
Maghazachi AA, Sand KL, Al-Jaderi Z
Frontiers in immunology 2016;7:437
Frontiers in immunology 2016;7:437
Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Goteri G, Rupoli S, Campanati A, Zizzi A, Picardi P, Cardelli M, Giantomassi F, Canafoglia L, Marchegiani F, Mozzicafreddo G, Brandozzi G, Stramazzotti D, Ganzetti G, Lisa R, Simonetti O, Offidani A, Federici I, Filosa G, Leoni P
The British journal of dermatology 2012 May;166(5):948-52
The British journal of dermatology 2012 May;166(5):948-52
Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.
Kaporis HG, Guttman-Yassky E, Lowes MA, Haider AS, Fuentes-Duculan J, Darabi K, Whynot-Ertelt J, Khatcherian A, Cardinale I, Novitskaya I, Krueger JG, Carucci JA
The Journal of investigative dermatology 2007 Oct;127(10):2391-8
The Journal of investigative dermatology 2007 Oct;127(10):2391-8
Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.
Fujita Y, Abe R, Sasaki M, Honda A, Furuichi M, Asano Y, Norisugi O, Shimizu T, Shimizu H
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 May 1;12(9):2670-5
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 May 1;12(9):2670-5
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- CCL27/CTACK in Human Skin. CCL27/CTACK was detected in immersion fixed paraffin-embedded sections of human skin using Mouse Anti-Human CCL27/CTACK Monoclonal Antibody (Catalog # MAB376) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in keratinocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by CCL27/CTACK and Neutralization by Human CCL27/CTACK Antibody. Recombinant Human CCL27/CTACK (Catalog # 376-CT) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR10 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL27/CTACK (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL27/CTACK Monoclonal Antibody (Catalog # MAB376). The ND50 is typically 0.5-3.0 µg/mL.
